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Abstract
Background
The Epstein–Barr virus (EBV) is the causative agent of infectious mononucleosis. EBV is
highly prevalent lymphotropic herpesvirus and has been linked to several malignancies.
Transmission is generally by oral secretions, but can be through blood transfusions and
organ transplantations. This study aimed to determine the seroprevalence, viremia rates,
and circulating genotypes of EBV in healthy blood donors in Qatar.
Methods
Blood samples from 673 blood donors of different nationalities residing in Qatar (mainly
Qatar, Egypt, Syria, Jordan, Pakistan, and India) were collected and tested for anti-EBV
capsid (VCA; IgG & IgM), nuclear (EBNA; IgG), and early (EA-D; IgG) antigens. Avidity test-
ing was determined when active infection was suspected. DNA was extracted from the buffy
coat and subjected to EBV-DNA quantification using qRT-PCR. Genotyping was performed
using nested-PCR targeting EBV-EBNA2 gene, and phylogeny by sequence analysis of the
LMP-1 gene.
Results
97.9% (673/659) of the samples were seropositive as indicated by the presence VCA-IgG,
while 52.6% (354/673) had detectible EBV-DNA. EBV seroprevalence and viremia rates
increased significantly with age. Genotyping of 51 randomly selected samples showed pre-
dominance of Genotype 1 (72.5%, 37/51) as compared to genotype 2 (3.5%), and mixed
infections were detected in 4% of the samples. Sub-genotyping for these samples revealed
that the Mediterranean strain was predominant (65.3%), followed by B95.8 prototype and
North Carolina strains (12.2% each), and China1 strain (6%).
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Conclusion
As a first study to evaluate EBV infection in highly diverse population in Qatar, where expa-
triates represent more than 85% of the population, our results indicated high seroprevalence
and viremia rate of EBV in different nationalities, with genotype 1 and Mediterranean strain
being predominant. Clinical significance of these finding have not been investigated and
shall be evaluated in future studies.
Introduction
Epstein Barr virus (EBV), or human herpesvirus 4, is a lymphotropic herpesvirus and the caus-
ative agent of infectious mononucleosis. Although the virus was first discovered in cells iso-
lated from African Burkitt’s lymphoma, further studies revealed its high prevalence worldwide
[1]. Like other herpesviruses, EBV causes latent infection. It primarily infects epithelial cells
and spreads to B lymphocytes where it persists for life [2]. In normal hosts, B lymphocytes and
epithelial cells are the cellular targets for EBV primary infection. However, EBV can infect a
wide range of non-B lymphocytes which determine the development and pathogenesis of EBV
related diseases [3]. It is estimated that more than 90% of the world’s population is EBV-sero-
positive [4]. Typically, primary infection with EBV occurs in childhood resulting in mild or no
disease, however, adulthood infection with the virus may lead to infectious mononucleosis
(IM) [5]. Further, this virus has been linked to a wide range of diseases including multiple scle-
rosis (MS), and malignancies, such as gastric carcinoma, Hodgkin’s lymphoma and nasopha-
ryngeal carcinoma (NPC) [4–7].
EBV encompasses a 172 kbp double stranded DNA genome that codes for more than 85
genes [5, 6]. In latency, only small subset of viral genes are expressed, which include the six
EBV nuclear proteins: EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, and
three latent membrane proteins: LMP-1, LMP-2A, LMP-2B [5].
There are two main EBV genotypes, Type 1 and Type 2, or Type A and B, distinguished by
the differences in the EBNA-2 gene, which exhibits only 54% homology between the two types
[8]. EBV types 1 and 2 can further be subdivided into different virus strains based on the
genetic diversity of LMP-1gene, which shows greater degree of polymorphism than most EBV
genes [9]. LMP-1 is a 356-amino acid protein, which consists of a short cytoplasmic N-termi-
nus, six membrane spanning domains, and a long cytoplasmic C- terminal domain [10]. LMP-
1 plays an important role in signal transduction and cell survival [6]. Variants in LMP-1 were
classified into 7 main groups: B95-8, Alaskan, China 1, China 2, Med+, Med- and NC [4, 6,
11]. However, new strains were subsequently reported from different origins, including two
new strains from Thailand, Southeastern Asia 1 (SEA1), and Southeastern Asia 2 (SEA2),
which have unique amino acid substitutions [12, 13]. Multiple EBV variants could be detected
within one individual, which could affect disease induction and prognosis [14]. For example, a
variant LMP-1 gene with 30 bp deletion gene was detected in virus isolated from NPC tumor
and was associated with a higher transforming activity compared to the typical prototype
LMP-1 (B95-8) [15, 16]
EBV is primarily transmitted through the oral route; however, it has been reported that
blood transfusion and organ transplantation are also other feasible transmission routes of EBV
[17–19]. Although blood-banking organizations adopt strict regulations to minimize the risk
of transfusion transmission of pathogens, nonetheless, there are still concerns regarding trans-
mission of untested pathogens, such as EBV [20]. Blood banks rely on the leukoreduction
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process to ensure the safety of blood products. Although leukoreduction procedure can point-
edly reduce the number of EBV genome, it has been found that EBV can still be detected in
leukoreduced products [21]. In conclusion, leukoreduction doesn’t completely eliminate cells
harboring EBV, which might poses a potential risk for blood products recipients, especially in
the immunocompromised [20, 21].
The lack of a licensed protective vaccine or specific treatment against EBV increases the
risk of EBV spread. The vast majority of published studies on EBV prevalence are focused on
serological analysis rather than viremia detection [22–26]. Clearly, detection of circulating
EBV DNA is a better indication of infection status, which can contribute to improving the
level of medical care prevention measures [27, 28]. Only few studies have looked at EBV vire-
mia in healthy subjects by detecting blood DNA [29–31]. Previous studies fromMiddle East-
ern countries such as Jordan [32], Kuwait [33], Egypt [34], Saudi Arabia [35], the UAE [36],
and Syria [37] have investigated EBV and its association with certain diseases such as Hodg-
kin’s lymphoma (ranging from 28% to 87%), but not among healthy individuals. To the best of
our knowledge, no studies have been conducted in Qatar or the region concerning EBV detec-
tion and genotyping in neither cancer patients nor healthy donors. Importantly, population in
Qatar is multinational with expatriates constituting more than 85% [38]. This study aimed at
estimating the EBV infection rates among healthy blood donors in Qatar, and determining the
demographic distribution of genotypes and sub-genotypes in relation to gender, age, and eth-
nicity. This information will enable the health officials in Qatar to consider the development of
new policies that aim at reducing the burden of communicable diseases related to blood
transfusion.
Materials and methods
Sample collection and ethical approval
A total of 673 whole blood samples (223 from Qataris and 450 from other nationalities) were
collected in EDTA tubes from healthy donors at the Blood Donor Unit at Hamad Medical
Corporation (HMC) over a period of one year (September 2014 –September 2015). Blood sam-
ples were handled and stored following standard safety procedures and guidelines. This study
was approved by HMC-Institutional Review Board (HMC-IRB #14292/14) and Qatar Univer-
sity IRB (QU-IRB 518-EA/15). See ethical compliance section below.
Ethical compliance. All procedures performed in studies involving human participants
were in accordance with the ethical standards of the Hamad Medical Corporation (HMC)
and Qatar University (QU). HMC-Institutional Review Board (HMC-IRB #14292/14) and
QU-IRB (#518-EA/15) were obtained before sample collection. This research involved no risk
to the subjects. Their rights and welfare was not affected. That is, samples were anonymously
collected and accompanied without names or sensitive information related to the patients.
Thus, a waiver of all the consent requirements was obtained before starting sample collection
from both QU and the HMC IRB committee. Only general information (age, sex, and nation-
ality) was collected and kept confidential.
Anti-EBV serology testing
Qualitative ELISA testing of anti- EBV antibodies. To determine EBV seroprevalence,
commercial ELISA kits (Diagnostic Automation, USA) were used to screen plasma samples
for the presence of EBV antibodies. A panel test was performed; this included screening anti-
bodies for: viral capsid antigen (VCA) [both VCA- IgG (Catalog # 1405–2), and VCA- IgM
(Catalog # 140692)], Epstein Barr nuclear antigen -1 (EBNA-1) -IgG (Catalog # 1425–1), and
EBV early antigen (EA)-IgG (Catalog # 1415–11). All ELISA assays were based on the same
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principle. In each kit, purified EBV antigens were coated on the surface of polystyrene micro-
wells to bind to the specific complementary antibodies. Kit controls were included in each
assay. For each assay, the cutoff calibrator value was calculated by multiplying the correction
factor which is specific for each kit, by the mean calibrator OD. The immune status ratio (IRS)
was calculated by dividing the samples OD value by the cutoff calibrator value. Samples were
considered positive if the IRS value was above the IRS cut-off value. Samples were retested
when the IRS value was in the equivocal range. According to the serological patterns obtained
from the ELISA screening of the four antibodies (VCA-IgG and IgM, EBNA-IgG, EA-IgG),
samples were classified into four stages (No infection, active infection, past infection, and
reactivation [39, 40]) according to the following criteria: 1. The presence of VCA-IgG and
VCA-IgM and EA-IgG in the absence of EBNA-IgG indicates acute primary infection; 2.
Presence of VCA-IgG only, or VCA-IgG and EBNA-IgG without VCA-IgM and EA-IgG indi-
cates past infection; and 3. Presence of VCA-IgG, EBNA-IgG and EA-IgG in the absence of
VCA-IgM indicates possible viral reactivation [41]. Samples yielding uncertain diagnosis such
as the positivity of all antibodies, or the presence of VCA-IgM and IgG with EBNA-IgG were
further investigated by VCA-IgG avidity assay to obtain a definitive diagnosis. Table 1 summa-
rizes the interpretation of EBV serological patterns.
Information related to patients, serology and PCR results are presented in S1 Table.
IgG avidity confirmatory test. VCA IgG avidity assay was performed when the ELISA
results produced a doubtful diagnosis, or when active infection was suspected. EBV capsid
antigen (EBV-CA) avidity determination kit (Cat # EI 2791-9601-1 G, Euroimmun, Germany)
was used. Briefly, two microplate ELISA tests were performed at the same time. One plate was
used for conventional ELISA procedure, and the other plate was treated with 8 M urea as a dis-
sociating agent to separate low avidity antibodies. Following the manufacturer’s instructions,
urea was added after the incubation period with patient’s serum, and before adding the sec-
ondary anti-human IgG. The difference in the reading with or without urea treatment in both
plates was evaluated by photometric measurement at wavelength of 450 nm. Moreover, for a
reliable interpretation, the relative avidity index (RAI) was calculated to compare between val-
ues with and without urea; RAI = the value with urea / value without urea. High RAI values
indicated past infection, while low RAI values indicated acute infection [42].
PMNCs separation
Ficoll-Paque PLUS (GE Healthcare Life Sciences, USA) was used for the isolation of lympho-
cytes from blood samples (n = 673) collected in EDTA tubes as per manufacturer’s instruc-
tions. Briefly, 1X Hank’s balanced salt solution (Life Technologies, USA) was used for 1:1
dilution of the blood samples and the diluted blood was layered over the Ficoll-Paque PLUS
solution. After centrifugation at 400× g for 30–40 minutes at 20˚C, blood cells differentially
migrated, resulting in the formation of different layers containing different cell types. The
Table 1. Interpretation of EBV serological pattens in immunocompetent individuals a.
Interpretation Anti- EBV antibodies
VCA- IgM VCA-IgG EBNA-IgG EA-IgG
No infection - - - -
Acute infection + + - +
Past infection - + + -
Reactivation - + + +
a Summarized from References [39–41].
https://doi.org/10.1371/journal.pone.0189033.t001
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layer in the bottom contained aggregated erythrocytes, and the buffy coat containing polymor-
phonuclear cells (PMNCs), including lymphocytes, were at the interface between Ficoll reagent
and the plasma. Plasma was discarded and PMNCs were collected in a separate tube. Finally,
PMNCs were subjected to short washing steps using a balanced salt solution to remove any
platelets, Ficoll-Paque PLUS and remaining plasma. Isolated PMNC were stored at -20˚C in
PBS until performing DNA extraction.
DNA extraction
DNA was extracted from PMNCs (buffy coat samples) suspended in 200 μl of PBS using Qia-
gen kit following the manufacturer’s instructions (Catalog # 51106, Qiagen, Germany). The
concentration and the purity of all extracted DNA samples were measured using NanoQuant
microplate reader (Infinite pro200, Tecan, Switzerland). Extracted DNA samples were then
stored at -20˚C for further testing.
EBV DNA detection by real time PCR
Detection and copy number quantification of EBV DNA in all extracted samples (n = 673)
were performed using a real-time PCR detection and quantification kit (Catalog # V48-
100FRT, Sacace, Italy) using 10 μl of DNA as per manufacturer’s instructions. The principle of
the detection in this kit is based on using real time amplification with fluorescent reporter dye
probes specific for EBV LMP gene. This kit also contained an indigenous internal control (IC)
that amplifies β-globin gene. QuantStudio™ 6 Flex Real-Time PCR reader (Applied Biosystems,
USA) was used for detection of the fluorescent dyes. Calibrators were used to construct the
standard curve that was used to quantify EBV copies in the tested samples. The reaction was
considered valid only if the quantity of IC was more than 2000 copies per reaction, and no
amplification was detected in the negative control. EBV viral load was calculated in copies per
reaction, copies per one microgram of extracted DNA, and copies per one ml of blood.
EBV genotyping by nested PCR of the EBNA-2 gene
EBV genotyping was performed using nested PCR targeting the EBNA2 gene as previously
described [43, 44]. Briefly, in the first round of amplification, primers E2p1 (5’-AGGGAT
GCCTGGACACAAGA-3’) and E2p2 (5’-TGGTGCTGCTGGTGGTGGCAA T-3’) were used
to amplify a fragment of 596 bp covering almost the entire EBNA2 gene. In the second round
of amplification, primers Ap1 (5’- TCTTGATAGGGATCCGCTAGGATA-3’) and Ap2 (5’-
ACCGTGGTTCTGGACTATCTGGATC-3’), were used to amplify a 497 bp fragment which
identifies the EBV type-1 EBNA2 gene product, whereas primers Bp1 (5’-CATGGTAGCCT
TAGGACATA-3’) and Bp2 (5’-AGACTTAGTTGATGCCCTAG-3’) amplified a 150 bp frag-
ment that characterizes EBV type-2 EBNA2 gene product. Samples with mixed EBV infections
were characterized by the presence of two amplicons, 479 bp in length using AP primers, and
150 bp using BP primers. PCR reaction of 50 μl was prepared in 0.2 ml microcentrifuge tube
using HotStarTaq DNA Polymerase kit (Catalog # 203203, Qiagen, Germany). Reaction mix
contained 0.25 μl of HotStarTaq DNA Polymerase, 10 μl of 5x Q-Solution, 5 μl of 10x PCR
buffer which already contained 15mMMgCl2, and 1 μl of 10mM dNTP’s (Catalog # N0447S,
New England Biolabs, USA). 1 μl of 10μM/ μl of one set of the above primers were added to
the mixture. For the first round of PCR using E2p1 and E2p2 primers, amplification condi-
tions were as follows: after an initial heat activation step of 15 min at 95˚C, 40 cycles of amplifi-
cation were performed: denaturation for 5 min. at 95˚C, annealing for 1 min. at 58˚C, and
extension for 1 min. at 72˚C, followed by a final extension step of 10 min. at 72˚C. For the sec-
ond round of PCR, the same amplification conditions were used except for the annealing
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temperature: 63˚C was used for Ap1 and Ap2 primers, and 53˚C was used for Bp1 and Bp2
primers. PCR amplified products were separated on 2% agarose and visualized using UV gel
documentation system (Bio-Rad, US). In all experiments, a negative control (sterile water
instead of DNA) and a positive control were used.
EBV sub-genotyping by sequencing of LMP-1 gene
Nested PCR of LMP-1 gene. EBNA-2 genotyped samples were further sub-genotyped tar-
geting LMP-1 gene, which has a high degree of polymorphism among EBV genes [4]. A nested
PCR of the LMP-1 gene was done as previously described [9], in the first round of amplifica-
tion, primers A1 (5’-AGTCATAGTAGCTTAGCTGAA-3’) and A2 (5’-CCATGGACAACGA
CACAGT -3’) were used to amplify a fragment of 602 bp covering the C-terminus of LMP-1
gene In the second round of amplification, primers B1 (5’-AGTCATAGTAGCTTAGCTGAA-
3’) and B2 (5’- CAGTGATGAACACCACCACG-3’) amplified a 587 bp fragment [9]. PCR
reactions were prepared similar to the EBNA-2 amplification procedure and using the same
kit and reagents, but with the designated primers. Amplification conditions were as follows:
initial heat activation step of 15 min at 95˚C; 40 cycles of PCR amplifications: 5 min. at 95˚C, 1
min. at 53˚C and 1 min. at 72˚C; and a final extension step of 10 min. at 72˚C. Amplified prod-
ucts were analyzed by 2% agarose gel electrophoresis and visualized using UV gel documenta-
tion system. In each experiment, a negative control (sterile water instead of DNA) and positive
control were used.
Cloning
LMP-1 PCR products from 51 randomly selected samples were cloned, sequenced and com-
pared to sequences deposited in NCBI GenBank followed by phylogenetic analysis. To do that,
PCR products (587 bp) were purified using PCR purification kit (Qiagen; Germeny), and
cloned by TA-cloning into pDrive vector using Qiagen cloning kit following the manufactur-
ers’ instructions. As previously described by AbuOdeh et al [45], three μl of the ligated plas-
mids were transformed by electroporation into 50 μL E. coli DH5α electrocompetent cells
(Invitrogen, USA). Transformed cell were then allowed to recover using 300 μl SOC broth
(Invitrogen) and incubated with shaking for 30 min at 37˚C. The 300 μl of SOC bacterial sus-
pensions were then spread on LB Agar containing 100 μg/ml ampicillin (Sigma, USA). Follow-
ing an overnight incubation, several distinct colonies from each culture plate were randomly
picked, suspended in LB broth containing 100 μg/ml ampicillin and grown with shaking for 24
hrs. Plasmids were purified from cultured bacteria using a QIAprep1 Spin Miniprep Kit (Cat-
alog # 231122, Qiagen, Germeny). Prior to sequencing, amplicons were examined for the pres-
ence of the cloned PCR products using restriction digestion with EcoRI enzyme. Digested
samples were then analyzed in 2% agarose gel electrophoresis. Plasmids harboring the cloned
fragment yielded a 587 bp band and a thicker large plasmid band. Samples were subsequently
sequenced at MC lab (California State, U.S.) using ABI 3730XL sequencer, using T7 forward
primer and Sp6 reverse primer.
Phylogenetic analysis
LMP-1 gene nucleotide sequences were translated to amino acid sequences and CLC sequence
viewer (version 7.1.1. Aarhus, Denmark) was used to run sequence alignments and construct
the phylogenetic tree. For sequence homology comparison, sequences were compared to refer-
ence sequences representing the seven main EBV strains available in the GenBank database:
B95.8 prototype strain (V01555), Med + with 30-bp deletion (AY337721), Med -without 30-bp
deletion (AY493810), China 1 (AY337723), China 2 (AY337724), Alaskan (AY337725), and
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NC strain (AY337726). As previously described by Saechan et al [13], sequences were aligned
using Clustal Wmethod, and the phylogenetic tree was generated using the neighbor joining
method. Bootstrapping and reconstruction were carried out with 1000 replicates to obtain the
confidence level of the phylogenetic tree.
Statistical analysis
To determine the relation significance between variable ratios, chi-square test was used. For
the correlation between EBV serology and real time PCR results, Kruskal Wallis test and
Mann–Whitney U test were used. Results with p-value< 0.05 were considered statistically sig-
nificant. The statistics software SPSS.23 and GraphPad Prism 7.00 were used for data analysis.
Results
Seroprevalence of EBV among healthy blood donors in Qatar
Table 2 summarized the demography of the studied population. A total of 673 blood samples
were analyzed in the present study, of which, 659 samples (97.9%) were from males and 14
samples (2.1%) from females. The majority of the samples were obtained from non-Qatari resi-
dents (66.9%), and the rest were from Qatari individuals (33.1%). The age of participants ran-
ged between 19 and 68 years, (37.12 ± 9.3 years).
Initially, all plasma samples (673) were screened for the presence of anti-EBV antibodies
(VCA- IgG, VCA- IgM, EBNA1-IgG, EA-IgG) using ELISA. 97.9% (659/673) of the samples
were seropositive for at least one of the aforementioned anti-EBV antibodies. A seroprevalence
of 91.5% (n = 616) was detected for anti-EBNA IgG antibodies. High percentage of samples
97.9% (n = 659) were positive for VCA- IgG, while only 1.8% (n = 12) were positive for IgM
class antibodies targeting the same gene. 10.6% (n = 71) samples tested positive for EA-IgG
antibodies.
VCA IgG avidity assay was then performed as it distinguishes between past and active infec-
tion. The strength of IgG binding was evaluated in all samples that showed ambiguous serolog-
ical interpretation and for samples with suspected active infection (n = 15). All tested samples
(n = 15) had high RAI, which indicates the presence of high avidity mature IgG antibodies,
Table 2. Demographic characteristics of the studied subjects (Total N = 673).
Category No. (%)
Gender
Male 659 (97.9)
Female 14 (2.1)
Nationality
Qatari 223 (33.1)
Male 219 (98.2)
Female 4 (1.8)
Non-Qatari 450 (66.9)
Male 440 (97.8)
Female 10 (2.2)
Age
<20–30 176 (26.15)
31–40 264 (39.2)
41–50 174 (25.9)
>50 59 (8.8)
https://doi.org/10.1371/journal.pone.0189033.t002
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thus, excludes the possibility of an active infection. Accordingly, final serological analysis indi-
cated that the majority of individuals (594 out of 679; 88.26%) had a past infection with the
virus, while only 9.7% (n = 65) had viral reactivation. Further, there was no sign of past EBV
infection in the remaining 2.1% (n = 14) samples (Table 3).
Association of EBV seroprevalence with age, gender, and nationality
Association between EBV seroprevalence and gender, age, and geographic origin of the partic-
ipants was performed using chi-square test. There was no statistically significant association
(p = 0.58) between EBV seroprevalence and gender, male (97.7%) and females (100%), proba-
bly because of the difference in samples size between the two groups.
Since Qatar is a multinational country where expatriates constitute more than 85% of the
population [38], we investigated EBV frequency between Qataris (n = 223) and non-Qatari
(n = 450) residents, specifically, among six major nationalities: Syria (n = 95), Egypt
(n = 92), Jordan/Palestine (n = 61), India (n = 59), and Pakistan (n = 20). We found no sig-
nificant difference in EBV seroprevalence between Qataris and non- Qataris (p = 0.84),
where 218 out of 233 (97.8%) Qatari donors were seropositive compared to 441 out of 450
(98%) seropositive donors from other nationalities. Egyptians and Pakistanis had the high-
est rates of EBV seroprevalence (100%) followed by Indians (98.3%), Syrians (96.8%),
Qataris (97.8), and Jordanian/Palestinian nationalities (95.1%). There was no statistical sig-
nificance in EBV seroprevalence nor the stage of infection among the different nationalities
(p = 0.99) (Table 4)
We then investigated the correlation of EBV seroconversion and age of donors and expect-
edly, infection rates increased significantly with age (p = 0.03), from 96% seropositivity in indi-
viduals less than 30 years old to 100% in people above 40 years of age (Fig 1).
Table 3. EBV seroprevalence and viremia rates in the studied population (N = 673).
Category Total No. EBV serology EBV DNA
Positive p-value* Positive p-value*
No. (%) No. (%)
Gender
Male 659 645 (97.9) 0.581 347 (52.7) 0.467
Female 14 14 (100) 6 (42.9)
Nationality
Qatari 223 218 (97.8) 0.8358 123 (55.2) 0.296
Male 219 214 (97.7) 112 (51.1)
Female 4 4 (100) 2 (50)
Non-Qatari 450 441 (98) 229 (50.9)
Male 440 431 (97.9) 226 (51.4)
Female 10 10 (100) 4 (40)
Age Group
<20–30 176 169 (96) 0.037 79(44.8) 0.009
31–40 264 257 (97.3) 134(50.76)
41–50 174 174 (100) 100 (57.5)
> 51 59 59 (100) 40(67)
* Pearson Chi2 p-value
https://doi.org/10.1371/journal.pone.0189033.t003
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EBV viremia rates among healthy blood donors
Viral load was determined in 673 blood samples using quantitative real-time (qRT-PCR) tar-
geting LMP-1 gene. EBV DNA was detected in 52.6% (n = 354) samples. There was no signifi-
cant correlation between viremia rates and gender (males (52.8%) and females (42.9%)), or
nationality (Qataris (55.2%) and non-Qataris (51.1%)). However, there was a direct correlation
between viremia rates and age (p-value = 0.009) among tested donors. The lowest viremia rate
was detected in age group less than 30 years (44.8%) compared to donors above 51 years of age
(67%) (Table 3, Fig 1). Viral load in the positive samples ranged between 0.915–2585.5 copies/
ml of blood, with a mean of 68.23 copies/ml and SD of 183.5.
Table 4. EBV serology and viremia rates among major nationalities (N = 673).
Category Total No. Seropositive
o. (%)
Positive RT-PCR
No. (%)
p-value*
Nationality
Qatar 223 218 (97.8) 123 (55.2) 0.99
Syria 95 92 (96.8) 51 (53.7)
Egypt 92 92 (100) 47 (51.1)
India 59 58 (98.3) 28 (47.5)
Jordan/Palestine 61 58 (95.1) 28 (45.9)
Pakistan 20 20 (100) 13 (65)
Others 123 121 (98.4) 64 (52)
Total 673
* Pearson Chi2 p-value
https://doi.org/10.1371/journal.pone.0189033.t004
Fig 1. The correlation of EBV seroprevalence and viremia rates with the ages of donors. Both seroprevalence and viremia
rates increased significantly with age.
https://doi.org/10.1371/journal.pone.0189033.g001
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Correlation between serology and viremia rates
Correlation between ELISA serological data and EBV DNA in blood was investigated. All EBV
seronegative donors had undetectable EBV DNA in their blood (n = 14). 53% (315/594) of
individuals with past infection status had detectable levels of EBV DNA in their blood. Further,
60% (39/65) of the samples from individuals with reactivation stage were PCR positive for
EBV (Table 5).
Circulating EBV genotypes and sub-genotypes among blood donors
51 samples from different nationalities were randomly selected for genotyping targeting
EBNA2 gene. EBV type 1, which is common in Europe, America, China, and South Asia [4,
15] was predominant (72.5%) in both Qatari and non-Qatari populations. On the other hand,
23.5% (n = 12) of the samples were positive for type 2 and 3.9% (n = 2) of the samples had
mixed infections (Fig 2, S1–S3 Figs).
The 51 genotyped samples were further sub-genotyped by sequence analysis of the LMP-1
gene C-terminus region. Nested PCR was used to amplify a 587 bp product that was subse-
quently cloned into pDrived plasmid (S4 and S5 Figs). Three to six clones from each sample
(total of 200 clones) were sequenced using ABI 3730XL sequencer (Applied Biosystems, USA).
Table 5. Correlation between EBV serology and RT-PCR.
Category by ELISA Total No. EBV DNA detected by RT-PCR
Positive
No. (%)
Negative
No. (%)
Viral load
copies/ml of blood
Viral load
copies/μg of DNA
No infection 14 0 (0) 14 (100) 0 0
Past infection 594 315 (53) 279 (47) 0.915–2585.5 18.3–51,710
Reactivation 65 39 (60) 26 (40) 2.5–1026.8 50–20,586
Total 673 354 319 0.915–2585.5 18.3–51,710
https://doi.org/10.1371/journal.pone.0189033.t005
Fig 2. The distribution of EBV genotypes among Qatari and non- Qatari residents.
https://doi.org/10.1371/journal.pone.0189033.g002
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Generated sequences (coordinates 168160 to 168748) were translated to amino acid sequences,
and aligned in comparison to previously reported EBV strains (prototype B95-8, Med+, Med-,
China 1, China 2, Alaskan, NC) using Clustal Wmethod (Fig 3). Molecular Phylogenetic anal-
ysis by neighbor joining method and Kimura two-parameter algorithm were performed using
CLC sequence viewer 7.7.1. software (Fig 4). Mediterranean strain was the most prevalent
strain with a rate of 65.3% (32/ 49), 62.5% (20/32) of which were fromMed- strain (without 30
bp deletion). Prototype B95.8 and NC strains were detected at lower rates, 12.2% each. The
least represented was China 1 strain, which was detected in 3 individuals (6%). Interestingly,
two of the samples (4%) had mixed infection, where Med- and B95.8 were detected. Table 6
summarizes the sub-genotypes in relation to the nationality of the donors.
Discussion
EBV is known to cause infectious mononucleosis, and contributes to the pathogenesis of sev-
eral malignancies, including>95% of Burkitt’s lymphoma cases [46], 70–95% of Hodgkin’s
disease [47],>90% of Non-Hodgkin’s disease [48],> 90% of lymphoepithelioma-like gastric
carcinoma [49], 5–25% in gastric adenocarcinomas [48, 50] and>90% of lymphoproliferative
disorders in immunocompromised individuals [48]. In a recent study [51], the global burden
of EBV related deaths was estimated to be>140,000, accounting for 1.8% of all cancer fatali-
ties. Accordingly, laboratories around the globe regularly screen for this virus considering its
importance in cancer development especially in immunocompromised patients. In the Middle
Eastern region, there are few studies that describe the epidemiology of the virus, and none
have been conducted in Qatar. In this study, we report on the seroprevalence of EBV, and the
circulating types and genotypes among healthy blood donors in Qatar.
We found high EBV seroprevalence among healthy blood donors (97.9%), which is similar
to what have been reported worldwide [20, 52]. We found that 96% of blood donors less than
30 years old were EBV seropositive, and seropositivity rate increased to 100% in donors older
than 40 years. Similar findings were reported in various studies including a new study from
Thailand, where EBV seroprevalence increased with age reaching 100% for those above 40
years of age [26]. In another study conducted in the USA. in 2006, 94% of organ donors were
EBV seropositive, with a lower rate being reported among young age groups (< / = 35 year)
[53].
Due to the high number of seropositive samples (>90%), we found no significant difference
in rates of seropositivity between donors from various nationalities. Rates among Egyptian,
Indian and Pakistani nationalities in Qatar were similar to those reported in the donors’ coun-
tries of origin [5, 6, 54, 55].
Although the indirect immunofluorescence assay (IFA) is considered the gold standard for
EBV immune-diagnosis, enzyme immunoassay (EIA) is routinely used in diagnostics because
of its high throughput [56]. Such techniques in addition to others like ELISA are still preferable
and commonly used despite their high degrees of variability [42]. Further, these techniques
have been used to identify the stage of EBV infection by detecting antibodies to certain pro-
teins, which could mislead diagnosis or produce false results.
EBNA-1 antibodies are usually used to identify past infections as they appear 3 to 6 months
post infection [6, 57]. Nonetheless, 6.7% of the donors in our study that were categorized with
past infection, based on the detection of VCA-IgG, were negative for EBNA-1 antibodies. This
was not surprising considering that 5 to 10% of healthy people never develop EBNA-1 antibod-
ies [58]. Moreover, in immunosuppressed patients, loss of anti EBNA-1 is frequently reported
[59]. Cumulatively, [57]; our results supports and confirms other studies that the use VCA-IgG
Prevalence and molecular profiling of EBV among healthy blood donors in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0189033 December 11, 2017 11 / 20
Prevalence and molecular profiling of EBV among healthy blood donors in Qatar
PLOS ONE | https://doi.org/10.1371/journal.pone.0189033 December 11, 2017 12 / 20
is superior to EBNA-1 IgG in detecting previous exposure to EBV, as VCA-IgG was found in
all EBV seropositive individuals. [57].
On the other hand, IgG antibodies against EA are detected transiently in up to 3 months or
more during infection mononucleosis [59]. When EA-IgG is detected after convalescence it
indicates virus reactivation [60]. However, reactivation cannot be confirmed only by EA-IgG
detection. Several studies have shown that around 20% of previously infected individuals
retain EA-IgG for years [58]. Among our tested samples, 65 (9.7%) had detectable EA-IgG,
and therefore, were classified under EBV reactivation category. Yet, even though EBV reactiva-
tion is not rare among healthy individuals and it can occur periodically, these findings need to
be supported by other tests such as molecular testing [42], and by the clinical picture of the
patient/donor to confirm a past infection with persistent EA-IgG.
VCA- IgM is produced transitionally and it is an indication of recent primary infection.
Typically, VCA-IgM weans after convalescence (few weeks), and may persist for months [40],
and generally, does not appear after that in lifetime [42]. Although VCA IgM appears early
and helps in the diagnosis of acute EBV infection, there are some limitations concerning the
Fig 3. Alignment of the LMP-1 C-terminal amino acid sequences by Clustal W method using CLC 7.7.1 sequence
viewer software. Numbers on the top represent the amino acid position corresponding to the prototype (B95.8). Dots indicate
identical amino acid to the prototype sequence, while dashes indicate deletions.
https://doi.org/10.1371/journal.pone.0189033.g003
Fig 4. Phylogenetic tree of LMP-1 C-terminus amino acid sequences using neighbor-joining method
and Kimura two-parameter algorithm.
https://doi.org/10.1371/journal.pone.0189033.g004
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interpretation of VCA IgM data as it was found that some acutely infected children and adults
do not develop VCA-IgM [40]. Furthermore, EBV-IgM might cross-react with other antigeni-
cally related viruses, especially CMV [61, 62]. In the current study, 12 samples were positive
for VCA-IgM using ELISA, however, they all tested positive with VCA-IgG avidity assay, indi-
cating the presence of high avidity mature IgG antibodies, and eliminating the possibility of
carrying an active infection. Avidity assay is therefore important to validate the serological
profile and it has been found to be a reliable tool in EBV primary infection confirmation in
patients with undetectable VCA-IgM and in the differential diagnosis as well [24, 63]. This dif-
ferential serological profile, which has been reported in other studies as well, might be of clini-
cal significance and shall be further studies.
At the molecular level, 52.6% of the samples had detectable EBV DNA as measured by the
real-time PCR. High rates of EBV infection have been reported in healthy blood donors, reach-
ing up to 72% in one of the studies [31]. In another study with larger number of samples,
Nishiwaki et al. reported 39.5% viremia rate (377/953) in healthy individuals [64]. On the
other hand, viremia rates could be as low as (5.1% as reported in some studies [65]. EBV detec-
tion by PCR is highly affected by the specimen used (whole blood versus PBMC versus serum)
and the variation in sample types must always be considered when comparing different stud-
ies. Typically, healthy individuals do not carry EBV in their plasma, accordingly studies that
screened for EBV in serum of healthy individuals reported very low or undetected rates [66–
68].
Another advantage of EBV DNA detection is that it enables the differentiation between
acute and silent reactivations [66, 69–71]. We therefore investigated the correlation of EBV
viremia seroprevalence and the different antibodies in the blood. We also investigated the cor-
relation of ELISA results with EBV viral load. PCR results confirmed the ELISA results of the
seronegative group. On the other hand, only 60% of those classified with EBV reactivation
were PCR positive. EBV reactivation is defined by the presence of past infection antibodies
(VCA-IgG and EBNA1-IgG), combined with positivity of EA-IgG, which can also persist for
lifetime in around 20% of individuals [42, 58]. Hence, serological testing only cannot confirm
reactivation status or the exact reactivation time. Therefore, EBV DNA detection and viral
load quantification is used to assist in the diagnosis of EBV reactivation, although discrepan-
cies can be found between PCR and serology [69]. In our study, not all of the samples classified
serologically with reactive EBV infection were positive by PCR. In addition, there was no sig-
nificant difference when comparing EBV viral load between samples of different EBV infection
Table 6. Distribution of EBV LMP-1 sub-genotypes by donors’ nationalities.
Nationality Total No. EBV LMP-1 strains
Med NC B95.8 China 1 Co-infection(Med and B95.8)
Qatar 14 5 2 4 1 2
Jordan 6 6
Egypt 6 5 1
India 6 5 1
Syria 6 4 0 1 1
Palestine 4 4 0
Pakistan 3 2 1
Iran
KSA
2 1 1
1 1
Germany 1 1
Total 49 32 6 6 3 2
https://doi.org/10.1371/journal.pone.0189033.t006
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stages. High viral load was expected in donors with reactivation status, but we recorded no sig-
nificant difference when compared to those samples of past infection. This could be attributed
to the small sample size of the reactivation group (n = 65). Moreover, we detected EBV in the
isolated PBMC’s of blood donors rather than whole blood; hence, the viremia rates did not
reflect the actual situation of the donors with EBV reactivation. Furthermore, our study is
cross sectional and we only tested one sample point for each donor. Accordingly, there is a
possibility that we could have missed the viremia phase in some donors.
Our study revealed that genotype 1 is predominant across different nationalities, with an
average rate of 72.5%. This genotype is usually more prevalent in Europe, America, China, and
South Asia [4, 15], compare to genotype 2 that is more prevalent in African and Papua New
Guinean populations and that was detected in only in 23.5% of samples [6, 72]. Mixed infec-
tions were also detected in 2 out of 51 (3.9%) samples, which have been previously reported in
several other studies [29] [9, 73], noting that infection with one genotype does not provide
immunity against the other.
Further sub-genotypying analysis based on LMP-1 gene revealed the presence of four vari-
ants. Mediterranean strain was predominant (65.3%), with Med–being more prevalent than
Med +; found in 65.1% of all Med isolates. Prototype strain B95.8 and North Carolina strain
were found in 12.2%, and the least detected was China 1 strain (6%). Two samples (4%)
showed the presence of two different strains Med and B95.8 indicating multiple EBV infec-
tions. Previous studies showed that the B95-8 prototype strain is typically prevalent in Euro-
pean isolates, whereas the China 1 strain appears to be the most prevalent in American and
Asian isolates [13]. Mixed infection with more than one sub-genotype was previously reported
where three strains China 1, B95.8 and Med were detected in a normal host [74]. We did not
detect isolates that belonged to the SEA1, Alaskan, nor China 3 strains which are high-risk
strains and are associated with EBV illnesses [12].
This is the first study that defined the status of EBV seroprevalence, genotypes, and
sub-genotypes among healthy individual in Qatar and the Middle East. However, the
study has some limitations. Firstly, we had few females (n = 14) participants compared to
males (n = 659) and thus, rendering the comparison between two groups questionable.
Moreover, the study was limited to samples collected from donors above 18 years of age,
where most of participants were seropositive and a similar study with younger group is
needed, especially when investigating EBV seroconversion, transmission, and vaccine
administration.
In conclusion, our study corroborated previous studies that showed high seroprevalence of
EBV, affecting more than 95% the population in Qatar. More importantly, we have shown a
high viremia rate amongst participants (average of 52.6%), that significantly increased with
age. EBV genotype 1, and sub-genotype Med were the predominant (72.5% and 65.3%, respec-
tively) in the studied population. These data will increase awareness of EBV among researchers
and healthcare workers in Qatar and will promote the adoption of safety practices in health
care centers, especially in blood banks and organ transplant centers. Nonetheless, a wider anal-
ysis that includes younger participants, cancer patients, and patients with immunocompro-
mised health conditions, will be necessary to estimate the risk of the virus in the population
and to apply control and prevention measures when applicable.
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EBNA2 gene using E2P1 and E2P2 primers that amplified almost the entire EBNA2 gene.
(TIF)
S2 Fig. Agarose gel electrophoresis results for the second round of PCR amplification for
the EBNA2 gene using EBV type 1 specific primers (AP primers).
(TIF)
S3 Fig. Agarose gel electrophoresis results for the second round of PCR amplification for
the EBNA2 gene using EBV type 2 specific primers (BP primers).
(TIF)
S4 Fig. Agarose gel electrophoresis results for the PCR amplification of the C- terminus of
LMP-1 gene using primers that amplify a 587 bp fragment.
(TIF)
S5 Fig. Agarose gel electrophoresis results for the EcoRI restriction digestion of the pDrive
cloning plasmids harboring the LMP-1 PCR fragment. The 587 bp cloned fragments (Lane
1–7) were separated after digestion of the pDrive plasmid (upper thick band) with EcoRI.
(TIF)
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